modelMagnesiumOxide
Extends from Pharmacolibrary.Drugs.ATC.A.A12CC10.
Information
| name: | MagnesiumOxide | |
| ATC code: | A12CC10 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 25 | L |
| clearance: | 6 | L/hr |
| other parameters in model implementation | ||
Magnesium oxide is an inorganic compound commonly used as a mineral supplement to prevent or treat low levels of magnesium in the body. It can also be used as an antacid to relieve heartburn, sour stomach, or acid indigestion, and as a laxative for short-term, rapid emptying of the bowel. It is an approved medication, available over-the-counter in many countries.
Pharmacokinetics
Estimated pharmacokinetic parameters for adult healthy individuals after typical oral administration, as there are no published detailed compartmental PK models for magnesium oxide using this ATC code. Values are based on published general information on magnesium absorption kinetics.
References
Kashihara, Y, et al., & Ieiri, I (2019). Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. European journal of clinical pharmacology 75(3) 351–361. DOI:10.1007/s00228-018-2568-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30382297
Hoy, SM, et al., & Wagstaff, AJ (2009). Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 69(1) 123–136. DOI:10.2165/00003495-200969010-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19192941
Schuette, SA, et al., & Janghorbani, M (1994). Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN. Journal of parenteral and enteral nutrition 18(5) 430–435. DOI:10.1177/0148607194018005430 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7815675
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)